A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 Study)

Japanese Journal of Clinical Oncology

Volumn 44, Issue 12, 2014, Pages 1216-1226

  Matsubara, Nobuaki ^a   Uemura, Hirotsugu ^b   Satoh, Takefumi ^c   Suzuki, Hiroyoshi ^d   Nishiyama, Tsutomu ^e   Uemura, Hiroji ^f   Hashine, Katsuyoshi ^g   Imanaka, Keiichiro ^h   Ozono, Seiichiro ⁱ   Akaza, Hideyuki ^j  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

^e NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^f YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^h Janssen Pharmaceutical KK   (Japan)

ⁱ HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j UNIVERSITY OF TOKYO   (Japan)

more..

Author keywords

Abiraterone acetate; Chemotherapy na ve; Metastatic castration resistant prostate cancer; Prednisolone; Prostate specific antigen

Indexed keywords

ABIRATERONE ACETATE; ANTIANDROGEN; BICALUTAMIDE; CHLORMADINONE ACETATE; CORTICOSTEROID; CYTOCHROME P450 INHIBITOR; DEGARELIX; DUTASTERIDE; ETHINYLESTRADIOL; FLUTAMIDE; FOSFESTROL; GOSERELIN; KETOCONAZOLE; LEUPRORELIN; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN; PYRROLE DERIVATIVE; 17-(3-PYRIDYL)-5,16-ANDROSTADIEN-3BETA-ACETATE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANTIANDROGEN THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CATARACT; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL ARTICLE; COMPRESSION FRACTURE; CONSTIPATION; CORTICOSTEROID THERAPY; CUSHINGOID SYNDROME; DIABETES MELLITUS; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; ENZYME DEFECT; FACE EDEMA; GLUCOSURIA; HEART ARRHYTHMIA; HEART DISEASE; HEART VENTRICLE TACHYCARDIA; HOT FLUSH; HUMAN; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; IMPAIRED GLUCOSE TOLERANCE; JAPANESE (PEOPLE); KIDNEY FAILURE; LEUKOCYTOSIS; LIVER DYSFUNCTION; LIVER TOXICITY; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OBESITY; OPEN STUDY; OSTEOPOROSIS; PATIENT HISTORY OF CHEMOTHERAPY; PHASE 2 CLINICAL TRIAL; PLEURISY; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; SPINE FRACTURE; STOMACH ULCER; SYSTEMIC THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; UROGENITAL TRACT RADIOGRAPHY; CLINICAL TRIAL; METABOLISM; METASTASIS; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROSTENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PREDNISOLONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84922527136     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyu149     Document Type: Article

References (26)

1. Prostate Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012; http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (3 May 2014, date last accessed). International Agency for Research on Cancer.
2. Cancer Statistics 2013 in Japan. http://ganjoho.jp/pro/statistics/en/backnumber/2005_en.html (3 May 2014, date last accessed).
3. Cancer Statistics 2005 in Japan. http://ganjoho.jp/pro/statistics/en/backnumber/2005_en.html (3 May 2014, date last accessed).
4. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23:8253-61.
5. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242-45.
6. Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2011;8:12-23.
7. Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217-27.
8. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447-54.
9. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-25.
10. Mizokami A, Koh E, Fujita H, et al. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 2004;64:765-71.
11. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
12. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-48.
13. Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26:4563-71.
14. Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010;28:1496-501.
15. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebocontrolled phase 3 study. Lancet Oncol 2012;13:983-92.
16. Rathkopf DE, Smith MR, de Bono JS. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castrationresistant prostate cancer patients without prior chemotherapy (COUAA-302). Eur Urol 2014. doi: 10.1016/j.eururo.2014.02.056.
17. Kawahara T, Miyoshi Y, Sekiguchi Z, et al. Risk factors for metastatic castration-resistant prostate cancer (CRPC) predict long-term treatment with docetaxel. PLoS ONE 2012;7:e48186.
18. Naito S, Tsukamoto T, Koga H, et al. Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan. Jpn J Clin Oncol 2008;38:365-72.
19. Ide H, Kikuchi E, Kono H, et al. Docetaxel in combination with prednisolone for hormone refractory prostate cancer. Jpn J Clin Oncol 2010;40:79-84.
20. Miura N, Numata K, Kusuhara Y, Shirato A, Hashine K, Sumiyoshi Y. Docetaxel-prednisolone combination therapy for Japanese patients with hormone-refractory prostate cancer: a single institution experience. Jpn J Clin Oncol 2010;40:1092-98.
21. Miyake H, Sakai I, Terakawa T, Harada K, Fujisawa M. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer. Urol Oncol 2013;31:733-38.
22. Ryan CJ, Shah S, Efstathiou E, et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 2011;17:4854-61.
23. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
24. Peer A, Gottfried M, Sinibaldi V, et al. Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel. Prostate 2014;74:433-40.
25. Beer TM, Armstrong AJ, Sternberg CN, et al. Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): results of phase III PREVAIL study. 2014 Genitourinary Cancers Symposium. J Clin Oncol 2014; 32(suppl 4; abstr LBA1).
26. Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA Guideline. J Urol 2013;190:429-38.